OvaScience Inc. (NASDAQ:OVAS) shares fell 5.8% on Tuesday . The company traded as low as $5.01 and last traded at $5.01, with a volume of 166,295 shares trading hands. The stock had previously closed at $5.32.

A number of brokerages recently weighed in on OVAS. Credit Suisse Group AG reaffirmed an “underperform” rating on shares of OvaScience in a research note on Friday, March 25th. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of OvaScience in a research note on Monday, April 25th. S&P Equity Research decreased their target price on shares of OvaScience from $10.82 to $8.83 in a research note on Monday, March 21st. Finally, Leerink Swann reissued a “hold” rating and issued a $7.00 target price (up from $6.00) on shares of OvaScience in a research note on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $12.37.

The stock’s market cap is $135.55 million. The company’s 50 day moving average is $5.78 and its 200-day moving average is $7.35.

OvaScience (NASDAQ:OVAS) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.08. During the same quarter last year, the business posted ($0.65) EPS. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.14 million. The firm’s revenue for the quarter was up 630.0% on a year-over-year basis. On average, equities research analysts forecast that OvaScience Inc. will post ($3.14) earnings per share for the current year.

In related news, Director Richard Aldrich bought 36,095 shares of the stock in a transaction on Friday, May 13th. The shares were bought at an average cost of $6.94 per share, for a total transaction of $250,499.30. Following the completion of the transaction, the director now owns 604,185 shares of the company’s stock, valued at approximately $4,193,043.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michelle Dipp bought 19,900 shares of the stock in a transaction on Tuesday, May 10th. The shares were bought at an average price of $7.72 per share, for a total transaction of $153,628.00. Following the completion of the transaction, the chief executive officer now directly owns 971,921 shares of the company’s stock, valued at approximately $7,503,230.12. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in OvaScience stock. AWM Investment Company Inc. increased its stake in OvaScience Inc. (NASDAQ:OVAS) by 1.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,352 shares of the company’s stock after buying an additional 1,352 shares during the period. AWM Investment Company Inc. owned approximately 0.43% of OvaScience worth $1,137,000 at the end of the most recent reporting period.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.